BQ Prime's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer BQ Prime's subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Centrum Broking Report
Aarti Drugs Ltd.'s Q4 FY24 result came above our estimate on all front, sales grew by 7% YoY (up 12% QoQ) to Rs 7.4 billion, mainly led by growth in the active pharma ingredient (10% YoY and 13% QoQ) and specialty chemicals (56% YoY and 29% QoQ).
-
Indian Markets Turning Corner After Two Tough Years, Says Sandeep Tandon -
NDTV Profit Ignite 2026: Experts See Opportunity In Equities, Stay Bullish For Long-Term -
Buy Right, Sit Tight Does Not Work for Individual Stocks, Says Dinshaw Irani -
'Worst Is Behind': Quant MF Sees Market Bottom, Flags 'Extreme Euphoria' In Midcaps -
India's Mutual Fund Industry Could Become A $1 Trillion Opportunity, Say Fund Managers -
'Foreign Investors Are Baraatis': Raamdeo Agrawal's Take On LTCG Tax -
Stay Invested Through Market Cycles: Raamdeo Agrawal at NDTV Profit Ignite -
Ramesh Damani Remains Bullish On India For Next 20-30 Years, Sees Bargains Amid Market Weakness -
CAS Came After A Long Consultation Process: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFIT IGNITE -
Aim To Cut FPI Onboarding Time From Mth To Five Days: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFI
On a sequential basis, the Ebitda margins improved by 196 basis points (flat YoY) to 12.6% due to operating leverage driven by improved capacity utilization.
Also Read | Layoffs Are Rising In Tech, But These Skills Are Helping People Unlock Better Pay
Aarti Drugs' profit after tax for the quarter came in at Rs 562 million flat on YoY (up by 53% QoQ).
Further, commercialisation of majority capex from FY24 onwards, new launches and revenue recovery led by specialty chemical and API growth would boost earnings by 38% compound annual growth rate over FY23-25E.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
